PDS Biotechnology (NASDAQ:PDSB) Downgraded by Wall Street Zen to "Sell"

PDS Biotechnology (NASDAQ:PDSB - Get Free Report) was downgraded by Wall Street Zen from a "hold" rating to a "sell" rating in a research note issued to investors on Saturday.

Separately, HC Wainwright reiterated a "buy" rating and issued a $13.00 target price on shares of PDS Biotechnology in a research note on Wednesday, June 11th.

PDS Biotechnology Stock Down 9.0%

Shares of PDSB stock traded down $0.16 on Friday, hitting $1.62. The stock had a trading volume of 578,933 shares, compared to its average volume of 495,539. The company has a quick ratio of 2.33, a current ratio of 2.33 and a debt-to-equity ratio of 0.29. The business has a 50 day moving average price of $1.37 and a 200 day moving average price of $1.46. The company has a market cap of $74.05 million, a PE ratio of -1.72 and a beta of 1.27. PDS Biotechnology has a one year low of $0.85 and a one year high of $4.42.

PDS Biotechnology (NASDAQ:PDSB - Get Free Report) last posted its earnings results on Wednesday, May 14th. The company reported ($0.21) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.25) by $0.04. Research analysts anticipate that PDS Biotechnology will post -1.2 earnings per share for the current fiscal year.

Institutional Investors Weigh In On PDS Biotechnology

Large investors have recently modified their holdings of the business. Two Sigma Investments LP grew its stake in shares of PDS Biotechnology by 273.5% during the fourth quarter. Two Sigma Investments LP now owns 65,732 shares of the company's stock worth $107,000 after acquiring an additional 48,132 shares during the last quarter. Jane Street Group LLC purchased a new stake in shares of PDS Biotechnology during the fourth quarter worth about $58,000. Raymond James Financial Inc. purchased a new stake in shares of PDS Biotechnology during the fourth quarter worth about $26,000. Blair William & Co. IL grew its stake in shares of PDS Biotechnology by 29.4% during the fourth quarter. Blair William & Co. IL now owns 157,500 shares of the company's stock worth $257,000 after acquiring an additional 35,757 shares during the last quarter. Finally, Virtu Financial LLC purchased a new stake in shares of PDS Biotechnology during the fourth quarter worth about $89,000. Hedge funds and other institutional investors own 26.84% of the company's stock.

About PDS Biotechnology

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies.